ABVC Biopharma Inc (ABVC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ABVC Biopharma Inc (ABVC) has a cash flow conversion efficiency ratio of -0.070x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-894.24K) by net assets ($12.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABVC defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
ABVC Biopharma Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how ABVC Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ABVC Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABVC Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mao Bao Inc
TW:1732
|
-0.013x |
|
Retail Food Group Ltd
AU:RFG
|
0.000x |
|
Dunia Virtual Online Tbk Pt
JK:AREA
|
0.063x |
|
WINSON Machinery Co Ltd
TWO:4538
|
0.020x |
|
Gabriel Resources Ltd
V:GBU
|
0.080x |
|
MERUS POWER OYJ EO 1
F:99H
|
N/A |
|
Farm Pride Foods Ltd
AU:FRM
|
0.183x |
|
iMBC Co.Ltd
KQ:052220
|
0.034x |
Annual Cash Flow Conversion Efficiency for ABVC Biopharma Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of ABVC Biopharma Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see ABVC Biopharma Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.30 Million | $-2.99 Million | -0.225x | +91.01% |
| 2024-12-31 | $723.96K | $-1.81 Million | -2.499x | +25.19% |
| 2023-12-31 | $1.25 Million | $-4.19 Million | -3.340x | -107.25% |
| 2022-12-31 | $4.59 Million | $-7.40 Million | -1.612x | -88.16% |
| 2021-12-31 | $8.87 Million | $-7.60 Million | -0.857x | -9.27% |
| 2020-12-31 | $5.82 Million | $-4.56 Million | -0.784x | -103.12% |
| 2019-12-31 | $-124.82K | $-3.13 Million | 25.113x | +22811.16% |
| 2018-12-31 | $-5.75 Million | $-630.20K | 0.110x | +116.02% |
| 2017-12-31 | $2.46 Million | $-1.68 Million | -0.684x | -228.39% |
| 2016-12-31 | $-6.52 Million | $-3.47 Million | 0.533x | +361.25% |
| 2015-12-31 | $29.08K | $3.36K | 0.116x | +202.37% |
| 2014-12-31 | $30.56K | $1.17K | 0.038x | -96.49% |
| 2011-12-31 | $-1.46 Million | $-1.59 Million | 1.088x | +211.17% |
| 2010-12-31 | $-2.99 Million | $-1.05 Million | 0.350x | -54.80% |
| 2009-12-31 | $-2.01 Million | $-1.56 Million | 0.774x | -58.93% |
| 2008-12-31 | $-1.24 Million | $-2.34 Million | 1.884x | +120.31% |
| 2007-12-31 | $290.29K | $-2.69 Million | -9.277x | -1438.21% |
| 2006-12-31 | $35.27K | $24.45K | 0.693x | +328.26% |
| 2005-12-31 | $60.67K | $-18.43K | -0.304x | -256.26% |
| 2004-12-31 | $87.34K | $-7.45K | -0.085x | -2021.11% |
| 2003-12-31 | $80.00K | $355.00 | 0.004x | +100.44% |
| 2002-12-31 | $10.00K | $-10.00K | -1.000x | -- |
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more